



Introducing MagPro XP with Cool TwinCoil for Magnetic Seizure Therapy

The MagPro XP with Cool TwinCoil is a high-performance investigational medical device for Magnetic Seizure Therapy (MST). MST is a novel form of seizure therapy that has been used in research for the past decade.

MST has been shown to achieve comparable clinical antidepressant efficacy as electroconvulsive therapy (ECT) in treating patients suffering from severe major depressive disorder, but with a superior cognitive side effect profile [1-8].

The MagPro XP with Cool TwinCoil builds on existing technology and comes with new technical features and design:





FEATURES

- Biphasic waveform, pulse width of 400 μ s and a maximal repetition rate of 250 Hz/pps.
- Delivers high-frequency magnetic stimulation at frequencies at or above seizure threshold
- Cool TwinCoil specifically for MST with two easily adjustable coils to ensure correct and optimal placement for MST and current direction indication on each coil
- Cool TwinCoil with ergonomic design and user friendly features such as additional handle for better grip and integrated trigger button
- Continuous operation or up to 6 patients/hour at maximum output without need to change coil and no risk of overheating
- Integrated system – all in one box (no trolley, no separate isolation transformers, no external coil cooler unit)
- Easy transportation due to ergonomic console design
- Two flexible displays for MagPro User Interface and patient monitoring
- Quick-stop button on the front panel
- Available in 3 different models for 3-phase 100 V, 3-phase 120V or 3-phase 230 V.

Optional Accessories: 6 channel ExG pod for patient monitoring, measuring EMG and EEG signals

Please note: the MagPro XP is IEC approved by UL in 2017 and is currently undergoing an initial CE marking. The MagPro XP is an investigational device and the use of the device requires approval by relevant authorities in the country where used.



SPECIFICATIONS

Electromagnetic Data with Cool TwinCoil

Waveform	Biphasic
Max. Rep. Rate	250 pps
Period time	370 μ s
PP-Current	20.5 KA
Maximal rise of current di/dt	203 A/ μ s

Performance Data – Amplitude Roll-Off

Output Power versus Repetition Rate (Typical Roll-off with Twin Coil):

Rep. Rate (pps)	Maximum Intensity
1 - 55	100 %
60	97 %
80	78 %
100	69 %
120	65 %
140	59 %
160	53 %
180	49 %
200	46 %
220	44 %
250	37 %

Mechanical Data for MagPro XP

Dimensions

MagPro XP without accessories

Width:	43.5 cm
Depth:	57.5-63 cm
Height to top base:	108 cm
Height with display min.	128.5 cm



Height with display max. 151.5 cm

Weight

MagPro XP (100V/120V): 207kg / 456 lbs

MagPro XP (230V): 175kg / 386 lbs

Mechanical Data for Cool TwinCoil

Weight

Total: 9.0kg / 19.8 lbs

Handheld weight: 7.0kg / 15.4 lbs

Dimensions

Cable length to grip: 1.4m / 4.6ft

Cable length to patient: 1.8m / 5.9ft

Power Supply

Inlet:

Mains Voltage depending on model:

100V 3N~, 50/60Hz

120V 3N~, 50/60Hz

230V 3N~, 50/60Hz

Maximum Power Consumption: Max. 10kVA

Standby Power Consumption: <230VA

Outlet:

4 pcs. Auxiliary outlets, IEC

230V~, 50/60Hz

Total max. 300VA



References

1. Kayser, S., *Magnetic Seizure Therapy in Treatment-Resistant Depression – Clinical, neuropsychological and metabolic effects*. 2014.
2. Polster, J.D., et al., *Effects of electroconvulsive therapy and magnetic seizure therapy on acute memory retrieval*. J ECT, 2015. **31**(1): p. 13-9.
3. Kayser, S., et al., *Comparable seizure characteristics in magnetic seizure therapy and electroconvulsive therapy for major depression*. Eur Neuropsychopharmacol, 2013. **23**(11): p. 1541-50.
4. Hoy, K.E., et al., *Effect of magnetic seizure therapy on regional brain glucose metabolism in major depression*. Psychiatry Res, 2013. **211**(2): p. 169-75.
5. Fitzgerald, P.B., et al., *Pilot study of the clinical and cognitive effects of high-frequency magnetic seizure therapy in major depressive disorder*. Depress Anxiety, 2013. **30**(2): p. 129-36.
6. White, P.F., et al., *Anesthetic considerations for magnetic seizure therapy: a novel therapy for severe depression*. Anesth Analg, 2006. **103**(1): p. 76-80, table of contents.
7. Lisanby, S.H., et al., *Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy*. Neuropsychopharmacology, 2003. **28**(10): p. 1852-65.
8. Soehle, M., et al., *Bilateral bispectral index monitoring during and after electroconvulsive therapy compared with magnetic seizure therapy for treatment-resistant depression*. Br J Anaesth, 2014. **112**(4): p. 695-702.